261947-64-2

Usage

Uses

1. Used in Pharmaceutical Industry:
1(2H)-Quinolinecarboxylic acid, 4-amino-2-ethyl-3,4-dihydro-6-(trifluoromethyl)-, ethyl ester, (2R,4S)is used as a pharmaceutical intermediate for the synthesis of various medicinal compounds. Its unique structure allows for the development of drugs with potential applications in treating a range of diseases.
2. Used in Chemical Research:
1(2H)-Quinolinecarboxylic acid,
4-amino-2-ethyl-3,4-dihydro-6-(trifluoromethyl)-, ethyl ester, (2R,4S)serves as a valuable research tool in the field of organic chemistry, particularly in the study of quinoline derivatives and their potential applications. It can be used to investigate the effects of different functional groups on the chemical properties and reactivity of the molecule.
3. Used in Material Science:
The complex structure of 1(2H)-Quinolinecarboxylic acid, 4-amino-2-ethyl-3,4-dihydro-6-(trifluoromethyl)-, ethyl ester, (2R,4S)makes it a candidate for the development of new materials with unique properties. It could be used in the synthesis of advanced materials for applications in electronics, optics, or other high-tech industries.
4. Used in Agrochemical Industry:
1(2H)-Quinolinecarboxylic acid,
4-amino-2-ethyl-3,4-dihydro-6-(trifluoromethyl)-, ethyl ester, (2R,4S)may also find applications in the agrochemical sector, where it could be used as a starting material for the synthesis of new pesticides or other agrochemical products, potentially leading to more effective and environmentally friendly solutions for crop protection.

Upstream product

• 474645-96-0 (2R,4S)-(2-ethyl-6-trifluoromethyl-1,2,3,4-tetrahydroquinolin-4-yl)carbamic acid benzyl ester 
• 667937-05-5 (3R)-3-(4-trifluoromethylphenylamino)pentanoic acid amide 
• 402-43-7 p-trifluoromethylphenyl bromide 
• 474645-91-5 (R)-3-((4-(trifluoromethyl)phenyl)amino)pentanenitrile 
• 400090-60-0 (R)-3-aminopentanenitrile 
• 1140966-17-1 (2R,4S)-4-benzyloxycarbonylamino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester 

Downstream Products

• 866399-60-2 (2R,4S)-4-(3-bromobenzyl)amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester 
• 474645-94-8 (2R,4S)-2-ethyl-4-methoxycarbonylamino-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester 
• 866397-24-2 (2R,4S)-4-(5-bromopyrimidin-2-yl)amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

Fragment-based discovery of novel pentacyclic triterpenoid derivatives as cholesteryl ester transfer protein inhibitors

Cholesteryl Ester Transfer Protein (CETP) is an important therapeutic target for the treatment of atherosclerotic cardiovascular disease. Our molecular modeling study revealed that pentacyclic triterpenoid compounds could mimic the protein-ligand interactions of the endogenous ligand cholesteryl ester (CE) by occupying its binding site. Alignment of the docking conformations of oleanolic acid (OA), ursolic acid (UA) and the crystal conformations of known CETP inhibitor Torcetrapib in the active site proposed the applicability of fragment-based drug design (FBDD) approaches in this study. Accordingly, a series of pentacyclic triterpenoid derivatives have been designed and synthesized as novel CETP inhibitors. The most potent compound 12e (IC50:0.28?μM) validated our strategy for molecular design. Molecular dynamics simulations illustrated that the more stable hydrogen bond interaction of the UA derivative 12e with Ser191 and stronger hydrophobic interactions with Val198, Phe463 than those of OA derivative 12b mainly led to their significantly different CETP inhibitory activity. These novel potent CETP inhibitors based on ursane-type scaffold should deserve further investigation.

Inhibitors of cholesterol ester transfer protein

This invention relates to inhibitors of CETP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders mediated by CETP.

4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines

Cholesteryl ester transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.